Dual Artery Compression for Patent Hemostasis and Prevention of Radial Artery Occlusion: The Quebec Terry 2 Registry
Catheterization and Cardiovascular Interventions · 2026-04 · 107 (5) · 1594-1600
DOI: 10.1002/ccd.70511 ↗At a glance
Multizentrische Studie in Catheterization and Cardiovascular Interventions, published online on 2026-02-10. Written by Tomas A Cieza and 8 co-authors. Institution: Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec, Canada. Major MEDLINE topics: Radial Artery, Hemostatic Techniques, Arterial Occlusive Diseases, Cardiac Catheterization. Cited 1 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Foundation of the Institut Universitaire de Cardiologie et de Pneumologie de Québec, MedTEQ+.
Abstract (original language)
Background
Radial artery occlusion (RAO) is a common complication following transradial artery access (TRA). Patent hemostasis is recommended to reduce RAO. Prophylactic ulnar artery compression is a technique to increase the rate of patent hemostasis.
Aims
To evaluate the efficacy and safety of prophylactic ulnar artery compression in achieving patent hemostasis and preventing RAO after TRA with the Terry 2 , a novel dual artery hemostasis device.
Methods
Patients undergoing coronary catheterization in three Quebec hospitals were included. A specific patent hemostasis protocol was used with the device. Radial artery patency using digital oximetry was assessed after Terry 2 placement and prior to hospital discharge. Nursing workload and patient comfort were also assessed.
Results
A total of 578 patients were included and followed up for 30 days. The average age was 69 ± 11 years, and 70% were male. Right radial access was used in 91% of cases. The introducer size was 5 Fr in 80% of cases. Patent hemostasis was 100%. The average time to hemostasis was 121 ± 41 min. At 30 days, RAO was found in a single patient (0.2%). Patients reported a high level of comfort, with 92% feeling “comfortable or very comfortable.” A 10−15 min per patient reduction in nursing time was reported compared to standard single artery compression.
Conclusions
Dual artery compression with the Terry 2 is an effective and safe strategy for achieving patent hemostasis and preventing RAO after coronary catheterization via TRA. This approach is associated with high success rates, patient comfort, and a potential substantial reduction in nursing workload.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec, Canada.
- Hôpital de Chicoutimi, Québec, Canada.
- Hôtel Dieu de Québec, Québec, Canada.
ORCID profiles: Tomas A Cieza, Paola Ulacia-Flores, Olivier F Bertrand
Funding
- Foundation of the Institut Universitaire de Cardiologie et de Pneumologie de Québec
- MedTEQ+
Cite
APA
Cieza, T. A., Bonnenfant, F., MacHaalany, J., Ulacia-Flores, P., Ouarrak, S., Ruhl, A., Pomerleau, E., Lapierre, J., & Bertrand, O. F. (2026). Dual Artery Compression for Patent Hemostasis and Prevention of Radial Artery Occlusion: The Quebec Terry 2 Registry. Catheterization and Cardiovascular Interventions, 107(5), 1594-1600. https://doi.org/10.1002/ccd.70511
Vancouver
Cieza TA, Bonnenfant F, MacHaalany J, Ulacia-Flores P, Ouarrak S, Ruhl A, et al. Dual Artery Compression for Patent Hemostasis and Prevention of Radial Artery Occlusion: The Quebec Terry 2 Registry. Catheterization and Cardiovascular Interventions. 2026;107(5):1594-1600. doi:10.1002/ccd.70511
BibTeX
@article{Cieza2026,
author = {Cieza, Tomas A and Bonnenfant, Francis and MacHaalany, Jimmy and Ulacia-Flores, Paola and Ouarrak, Safia and Ruhl, Andres and Pomerleau, Erika and Lapierre, Joany and Bertrand, Olivier F},
title = {Dual Artery Compression for Patent Hemostasis and Prevention of Radial Artery Occlusion: The Quebec Terry 2 Registry},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {107},
number = {5},
pages = {1594--1600},
doi = {10.1002/ccd.70511}
}
EUVIMED